期刊文献+

益赛普与柳氮磺胺吡啶治疗强直性脊柱炎的Mete分析 被引量:13

Etanercept Versus Sulfasalazine for Patients with Ankylosing Spondylitis: A Systematic Review
下载PDF
导出
摘要 目的评价益赛普与柳氮磺胺吡啶治疗强直性脊柱炎的疗效和副作用。方法计算机检索Cochrane Library(2013年第3期),MEDLINE(1966~2013.10),EMbase(1974~2013.10),中国生物医学文献数据库(1978~2013.10),中国期刊全文数据库(1994~2013.10),中文科技期刊全文数据库(1989~2013.10),万方数据库(1980~2013.10)中所有益赛普与柳氮磺胺吡啶治疗强直性脊柱炎的随机对照试验和半随机对照试验。由两名评价员独立提取资料,并对其方法学质量进行评价。对符合纳入标准的研究用RevMan5.2软件进行Meta分析。结果共纳入7个研究940例患者,Meta分析结果示:益赛普较柳氮磺胺吡啶治疗强直性脊柱炎患者能有效提高达到ASA20的病例数[OR=2.71,95%CI(2.22,3.32)],改善治疗终点时Bath强直性脊柱炎测量指数(BASMI)[MD=-0.43,95%CI(-0.46,-0.40)],提高脊柱活动度(Schober试验)[MD=0.54,95%CI(0.04,1.03)],降低红细胞沉降率[MD=-6.23,95%CI(-7.83,-4.63)],降低C-反应蛋白[MD=-5.12,95%CI(-6.79,-3.45)]。在骶髂关节MRI炎症评分两药间差异无统计学意义[MD=-0.26,95%CI(-0.76,0.24)]。两种药物用药期间发生呼吸道感染事件差异无统计学意义[OR=1.33,95%CI(0.26,6.85)],发生胃肠道反应事件差异有统计学意义[OR=0.33,95%CI(0.12,0.89)]。结论益赛普较柳氮磺胺吡啶在改善患者功能,降低红细胞沉降率,炎症反应蛋白更有效,而且发生胃肠道反应的事件更少。 Objective To assess the efficacy and adverse events of Etanercept versus Sulfasalazine for patients with Ankylosing spondylitis. Methods We searched the Cochrane Library ( Issue 3. 2013), MEDLINE (1966 to October 2013),EMBASE (1974 to October 2008),CBM (1978 to October 2013), CNKI (1994 to October 2013 ), VIP ( 1989 to October 2013), and Wanfang ( 1999 to October 2013). The quality of included studies was critically evaluated. Data analyses were performed with The Cochrane Collaboration's RevMan 5.2 software. Results Seven randomized controlled trials with total of 940 patients met the included criteria. The meta analysis showed the effective rate of ASAS 20 and BASMI and the reduction of ESR and CRP receiving Etanercept was significantly higher than in patients receiving sulfasalazine. There was no statistical significance in the MRI sacroiliac joint score and the respiratory infection. The difference of causing the gastrointestinal re- action during treatment was statistically significant. Conclusions Etanereept compared with sulfasalazine in improving patient~ activities function,reducing the erythroeyte sedimentation rate, C -Reactive protein is more effective, what is more, also decreased the incidence of the gastrointestinal reaction.
出处 《宁夏医科大学学报》 2014年第5期545-552,共8页 Journal of Ningxia Medical University
关键词 益赛普 柳氮磺胺吡啶 强直性脊柱炎 Mete分析 etanercept sulfasalazine ankylosing spondylitis systematic review
  • 相关文献

参考文献17

  • 1Braun J,Sieper J.Ankylosing spondylitis[J].Lancet,2007,369:1379-1390.
  • 2Feldtkeller E,Khan MA,van der Heijde D,et al.Age at disease onset and diagnosis delay in HLA-B27negative vs positive patients with ankylosing spondylitis[J].Rheumatol Int,2003,23:61-66.
  • 3Braun J,Heijde VD.Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides[J].Expert Opin Investing Drugs,2003,12(7):1097-1109.
  • 4唐福林,吴东海.临床诊疗指南-风湿病分册[M].北京:人民卫生出版社,2005:23.
  • 5Higgins JPT,Green S.Cochrane handbook for systematic reviews of interventions version 5.1.0[updated March 2011].The Cochrane Collaboration,2011[OL].Available from:www.Cochrane-handbook.org.
  • 6Braun J,Vander Horst-Bruinsma IE,Huang F,et al.Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis[J].Arthritis & Rheumatism,2011,63(6):1543-1551.
  • 7Song IH,Hermann KG,Haibel H,et al.Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER):a 48-week randomised controlled trial[J].Ann Rheum Dis,2011,70:590-596.
  • 8赵福涛,赵浩,王艳玲.依那西普治疗强直性脊柱炎的疗效分析[J].上海交通大学学报(医学版),2009,29(12):1506-1508. 被引量:17
  • 9陈慕芝,照日格图,王海云,魏丽.重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白与传统免疫抑制剂治疗强直性脊柱炎的临床对照研究[J].新疆医科大学学报,2010,33(8):913-915. 被引量:7
  • 10罗莉,张新玉,孟岩,杜文静.磁共振成像在评价强直性脊柱炎疾病活动中的价值研究[J].新疆医科大学学报,2013,36(8):1138-1141. 被引量:4

二级参考文献64

  • 1赵福涛,管剑龙,韩星海.甲氨蝶呤治疗强直性脊柱炎髋关节病变的临床研究[J].中华风湿病学杂志,2007,11(4):213-216. 被引量:11
  • 2王莉莎,黄烽,张江林,邓小虎,张亚美,张莉芸,郭军华.肿瘤坏死因子拮抗剂在治疗强直性脊柱炎中的安全性分析[J].中国新药杂志,2007,16(7):556-561. 被引量:24
  • 3Sieper l, Braun J, Rudwaleit M, et al. Ankylosing spondylitis: an overview. Ann Rheum Dis, 2002, 61 (Suppl 3): iii8-iii18.
  • 4Braun J, Bollow M, Remlinger G, et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum, 1998, 41: 58-67.
  • 5Gran JT, Husby G, Hordvik M. Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromso, northern Norway. Ann Rheum Dis, 1985, 44: 359-67.
  • 6Braun J, Listing J, Sieper J. Reply. Arthritis Rheum, 2005, 52: 4049-4059.
  • 7Toussirot E, Wendling D. Current guidelines for the drug treatment of ankylosing spondylitis. Drugs, 1998, 56: 225-240.
  • 8Immunex Corporation. Enbrel (etanercept) for subcutaneous injection (2006). Available from URL: http://www.amgen.com/pdfs/misc/enbrel_pi.pdf.
  • 9Braun J, Heijde VD. Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides. Expert Opin Investing Drugs, 2003, 12(7): 1097-1109.
  • 10Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. Arthritis Rheum, 1984, 27: 361-368.

共引文献50

同被引文献128

引证文献13

二级引证文献82

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部